Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMP360 long-term follow-up in treatment-resistant depression
NL-OMON55052Phase 2Completed
- Sponsor
- COMPASS Pathways
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of COMP360 in treatment-resistant depression (TRD), sponsored by COMPASS Pathways. Started Jun 2021; status: completed.
02
Drugs
COMP360
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NL-OMON55052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55052.